Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3851/IMP3014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma.
Front Immunol
December 2024
Department of Oncology, Oslo University Hospital, Oslo, Norway.
Background: Pleural mesothelioma (PM) is a rare cancer with a dismal prognosis. Dual immune checkpoint inhibitors have improved overall survival, but the rate of immune-related adverse events (irAEs) is high. Serum cytokines reflect systemic immune reactions and may serve as biomarkers for irAEs.
View Article and Find Full Text PDFRuzotolimod (Toll-like receptor 7 (TLR7) agonist, RG7854) is an oral, small molecule immuno-modulator activating the TLR 7 and is being evaluated in patients with CHB. As with other TLR7 agonists, the study drug-related adverse events of flu-like symptoms have been reported in some participants during phase I studies with ruzotolimod. An exploratory analysis of the relationship between pharmacokinetic (PK)/pharmacodynamic (PD) and flu-like symptoms was performed in participants from two phase I studies including both healthy volunteers and NUC-suppressed CHB patients who received either single or multiple ascending doses of orally administered ruzotolimod.
View Article and Find Full Text PDFExpression of 10 circulating cytokines/chemokines in HBV-related liver disease.
Infect Agent Cancer
May 2024
The Third Central Clinical College of Tianjin Medical University, Tianjin, 300170, China.
Background: Cytokines/chemokines play essential roles in the occurrence and progression of hepatitis B virus (HBV) infection. This study aimed to observe the expression patterns of 10 related cytokines/chemokines in the serum of healthy individuals, self-limited patients and HBV-infected patients at different stages of disease (chronic hepatitis B (CHB), liver cirrhosis (LC), hepatocellular dysplastic nodules (DNs) and hepatocellular carcinoma (HCC)) and to analyze the relationships of these cytokines/chemokines with disease progression.
Methods: The levels of six cytokines (FGF-2, IFN-α2, IL-4, IL-6, IL-10 and VEGF-A) and four chemokines (GRO-α, IL-8, IP-10 and MCP-1) were quantified using Luminex multiplex technology.
Effect of high-dose supplementation on hospitalized adults with COVID-19: a randomized controlled trial.
Front Immunol
April 2024
Physical Activity, Lifestyle, Ageing and Wellbeing Faculty Research Group, School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Objective: () is a cyanobacterium proven to have anti-inflammatory, antiviral, and antioxidant effects. However, the effect of high-dose supplementation on hospitalized adults with COVID-19 is currently unclear. This study aimed to evaluate the efficacy and safety of high-dose for SARS-CoV-2 infection.
View Article and Find Full Text PDFThe evaluation of PD-1 and Tim-3 expression besides their related miRNAs in PBMCs of women with recurrent pregnancy loss.
Immunol Lett
April 2024
Department of Medical Biology and Central Electron Microscope Laboratory, Medical School, Pécs University, Pécs, Hungary; János Szentágothai Research Centre, Pecs University, Pecs, Hungary; Endocrine Studies, Centre of Excellence, Pecs University, Pecs, Hungary; MTA - PTE Human Reproduction Research Group, Pecs, Hungary; National Laboratory of Human Reproduction, Pécs, Hungary. Electronic address:
Recurrent pregnancy loss (RPL) is a multifactorial disorder, associated with immunologic abnormalities. During pregnancy, the maternal immune system uses different tolerance mechanisms to deal with a semi-allogenic fetus. The expression of immune checkpoints and their related miRNAs in immune cells can ensure pregnancy at the feto-maternal interface by modulating immune responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!